Veracyte, Inc. (VCYT): Price and Financial Metrics
VCYT Price/Volume Stats
| Current price | $22.90 | 52-week high | $32.40 |
| Prev. close | $22.58 | 52-week low | $14.92 |
| Day low | $22.58 | Volume | 49,861 |
| Day high | $23.16 | Avg. volume | 646,937 |
| 50-day MA | $25.62 | Dividend yield | N/A |
| 200-day MA | $24.87 | Market Cap | 1.67B |
VCYT Stock Price Chart Interactive Chart >
VCYT POWR Grades
- Sentiment is the dimension where VCYT ranks best; there it ranks ahead of 81.12% of US stocks.
- The strongest trend for VCYT is in Growth, which has been heading down over the past 177 days.
- VCYT's current lowest rank is in the Momentum metric (where it is better than 5.22% of US stocks).
VCYT Stock Summary
- Price to trailing twelve month operating cash flow for VCYT is currently 52.28, higher than 93.61% of US stocks with positive operating cash flow.
- For VCYT, its debt to operating expenses ratio is greater than that reported by just 10.95% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for VERACYTE INC; that's greater than it is for only 8.2% of US stocks.
- If you're looking for stocks that are quantitatively similar to VERACYTE INC, a group of peers worth examining would be PAYC, OSS, FUBO, PHUN, and AMSC.
- VCYT's SEC filings can be seen here. And to visit VERACYTE INC's official web site, go to www.veracyte.com.
VCYT Valuation Summary
- VCYT's price/earnings ratio is -56.3; this is 310.86% lower than that of the median Healthcare stock.
- Over the past 120 months, VCYT's price/sales ratio has gone down 18.6.
Below are key valuation metrics over time for VCYT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VCYT | 2023-09-22 | 5.0 | 1.5 | -56.3 | -50.8 |
| VCYT | 2023-09-21 | 5.0 | 1.5 | -56.6 | -51.1 |
| VCYT | 2023-09-20 | 5.2 | 1.6 | -58.4 | -53.0 |
| VCYT | 2023-09-19 | 5.3 | 1.6 | -60.4 | -55.0 |
| VCYT | 2023-09-18 | 5.4 | 1.6 | -60.9 | -55.5 |
| VCYT | 2023-09-15 | 5.5 | 1.7 | -62.7 | -57.4 |
VCYT Growth Metrics
- The 2 year revenue growth rate now stands at 105.47%.
- Its 4 year price growth rate is now at 247.13%.
- The year over year net cashflow from operations growth rate now stands at 100.15%.
The table below shows VCYT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 283.575 | 6.237 | -43.244 |
| 2022-06-30 | 268.353 | -2.182 | -48.65 |
| 2022-03-31 | 250.594 | 0.068 | -48.156 |
| 2021-12-31 | 219.514 | -31.621 | -75.563 |
| 2021-09-30 | 186.714 | -37.806 | -73.079 |
| 2021-06-30 | 157.465 | -34.661 | -63.074 |
VCYT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VCYT has a Quality Grade of D, ranking ahead of 19.15% of graded US stocks.
- VCYT's asset turnover comes in at 0.213 -- ranking 68th of 81 Healthcare stocks.
- CHE, HCSG, and NTRA are the stocks whose asset turnover ratios are most correlated with VCYT.
The table below shows VCYT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.213 | 0.673 | -1.427 |
| 2021-03-31 | 0.224 | 0.662 | -1.543 |
| 2020-12-31 | 0.327 | 0.647 | -0.827 |
| 2020-09-30 | 0.360 | 0.642 | -0.795 |
| 2020-06-30 | 0.425 | 0.652 | -0.693 |
| 2020-03-31 | 0.462 | 0.670 | -0.490 |
VCYT Price Target
For more insight on analysts targets of VCYT, see our VCYT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $63.17 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Veracyte, Inc. (VCYT) Company Bio
Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.
Latest VCYT News From Around the Web
Below are the latest news stories about VERACYTE INC that investors may wish to consider to help them evaluate VCYT as an investment opportunity.
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual MeetingSOUTH SAN FRANCISCO, Calif., September 21, 2023--Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from |
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s TestsSOUTH SAN FRANCISCO, Calif., September 07, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations. Dr. Taine is a highly credentialed commercial operations leader with 30 years of experience in the medical device and pharmace |
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer TherapiesSOUTH SAN FRANCISCO, Calif. & PARIS, September 06, 2023--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. The multi-year partnership will leverage Gustave Rou |
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing. In the past five years, the genetic diagnostics company Veracyte (NASDAQ: VCYT) has produced cumulative total returns of 116% for shareholders. |
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., August 29, 2023--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time. |
VCYT Price Returns
| 1-mo | -8.58% |
| 3-mo | -11.45% |
| 6-mo | 2.69% |
| 1-year | 35.10% |
| 3-year | -25.55% |
| 5-year | 139.79% |
| YTD | -3.50% |
| 2022 | -42.40% |
| 2021 | -15.82% |
| 2020 | 75.29% |
| 2019 | 121.94% |
| 2018 | 92.65% |
Continue Researching VCYT
Want to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:Veracyte Inc (VCYT) Stock Price | Nasdaq
Veracyte Inc (VCYT) Stock Quote, History and News - Yahoo Finance
Veracyte Inc (VCYT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...